Stockscreener 앱 받기
5.77
0.35%
0.02
시간 외 거래:
5.79
0.02
+0.35%
전일 마감가:
$5.75
열려 있는:
$5.89
하루 거래량:
156.05K
Relative Volume:
0.10
시가총액:
$36.45M
수익:
-
순이익/손실:
$-11.46M
주가수익비율:
-0.4121
EPS:
-14
순현금흐름:
$-24.56M
1주 성능:
-5.87%
1개월 성능:
+6.26%
6개월 성능:
+267.52%
1년 성능:
-55.44%
1일 변동 폭
$5.5101
$5.98
1주일 범위
$5.5101
$6.82
52주 변동 폭
$1.20
$13.80
에바종 바이오테크 Stock (EVAX) Company Profile
EVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
5.77 | 45.56M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
에바종 바이오테크 Stock (EVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-02 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | 개시 | H.C. Wainwright | Buy |
에바종 바이오테크 주식(EVAX)의 최신 뉴스
Evaxion raises $7.2 million, extending cash runway to second half of 2027 - GlobeNewswire Inc.
European ADRs Barely Budge While Gainers And Losers Trade Places - Finimize
Evaxion A/S (NASDAQ:EVAX) Given Buy Rating at HC Wainwright - Defense World
European ADRs Edge Higher As Healthcare Leads Gains - Finimize
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Sees Large Growth in Short Interest - Defense World
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough - ts2.tech
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
European Biotech Stocks Outperformed As Broader Market Dipped - Finimize
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Evaxion Biotech price target raised to $16 from $14 at H.C. Wainwright - MSN
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Evaxion Biotech out-licensed vaccine candidate EVX-B3 to MSDMerck - TipRanks
Evaxion A/S (NASDAQ:EVAX) Trading Down 0.7% – Should You Sell? - Defense World
Evaxion Biotech A/S Adr Earnings Call: Strategic Growth Amid Challenges - TipRanks
Evaxion Biotech Reports Q2 2025 Financial Results - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
XTX Topco Ltd Makes New Investment in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) - Defense World
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
European ADRs Dip With Some Stocks Rising Above The Crowd - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
Evaxion A/S: Shareholders Board Members Managers and Company Profile | US29970R3030 - MarketScreener
European Equities See Growth In US Trade - Finimize
Analysts’ Top Healthcare Picks: Encompass Health (EHC), Evaxion Biotech (EVAX) - The Globe and Mail
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
에바종 바이오테크 (EVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):